Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 5/20 | 0.32 |
| ▸ | RARB | P10826 | 5/20 | 0.32 |
| ▸ | RARG | P13631 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274978 | 0.82 | ACHE (0.32) | — | |
| SCHEMBL7839550 | 0.79 | RARA (0.32) | RARARARBRARGRXRA | |
| SCHEMBL6344022 | 0.78 | TP53 (0.36) | RARARARBRARGBACE1RXRA | |
| SCHEMBL6350807 | 0.75 | BACE1 (0.36) | RARARARBRARGBACE1 | |
| SCHEMBL6350746 | 0.74 | MEN1 (0.34) | RARARARBRARGRXRA | |
| SCHEMBL6032597 | 0.73 | RARA (0.32) | RARARARBRARG | |
| SCHEMBL7468595 | 0.73 | RARA (0.42) | RARARARBRARGBACE1RXRA | |
| SCHEMBL1649848 | 0.71 | RARA (0.40) | RARARARBRARGBACE1RXRA | |
| SCHEMBL6348329 | 0.68 | RARA (0.32) | RARARARBRARG | |
| SCHEMBL29531735 | 0.68 | TP53 (0.44) | RARARARBRARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| CN-109311839-B | Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer | 癌症研究协会皇家癌症医院 | 2021-11-02 | — | — | CN | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0350846-B1 | Condensed heterocyclic compounds and their use in therapy | HOFFMANN LA ROCHE (CH) | 1995-10-11 | — | — | EP | disclosed |
| EP-0405028-B1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN INC (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5420273-A | Skin disorders and antitumor agents | HOFFMAN-LA ROCHE INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5300522-A | Treating inflammatory, allergic, rheumatic, immunological disorders | HOFFMANN-LA ROCHE INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5164387-A | Antitumor agents, skin disorders, antiinflammatory agents | HOFFMANN-LAROCHE INC. (US) | 1992-11-17 | — | — | US | disclosed |
| US-5037825-A | Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin | HOFFMANN-LA ROCHE INC. (US) | 1991-08-06 | — | — | US | disclosed |
| US-5015658-A | Treatment of skin disorders such as psoriasis | ALLERGAN, INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0405028-A1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN, INC (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4895868-A | PSORIASIS, SKIN DISORDERS, ANTIARTHRITIC, WOUND HEALING, EYE DRYNESS | ALLERGAN, INC. (US) | 1990-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | RARA 3126/4885RARB 2472/4885RARG 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.